Clinical trials: Hematologic and Lymphocytic Disorder
Drug-Induced Liver Injury
A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases
This is a retrospective, multicenter real-world observational study. Its main goal is to find out if Polyene Phosphatidylcholine Injection works to treat drug-induced liver injury (DILI) in adults with hematologic malignancies…
- Trial name
- PPC-HM-DILI (NCT07476885)
- Testing
- polyene phosphatidylcholine
- Volunteers
- 1,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Thrombocytopenia, Hepatitis C
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L) the opportunity to undergo treatment and possible cure of their virus.
- Trial name
- SQUELCH-C (NCT01821625)
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
This phase I trial studies the side effects and best dose of lenalidomide after donor stem cell transplant and bortezomib in treating patients with high-risk multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01954784
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, T-Cell, NK-LGL Leukemia
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable.
- Conditions
- Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia, Cutaneous T Cell Lymphoma
- Trial name
- NCT06716658
- Testing
- JAK1 Inhibitor
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myelogenous leukemia cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with acute myelogenous…
- Trial name
- NCT00003148
- Testing
- aldesleukin
- Where
- 10 sites in Austria, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult
Lentivirally Redirected CD123 Autologous T Cells in AML
Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Refractory
- Trial name
- NCT03766126
- Testing
- CART123 cells; cyclophosphamide; fludarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Iron Deficiency, Iron Deficiency Anemia
Effect of Iron Fortified Wheat Flour on Cognition and Iron Status in Indian School Children
This study is designed to evaluate the efficacy of NaFeEDTA-fortified whole wheat flour in improving cognition, hemoglobin, iron status and total body iron among school children in urban Bangalore.
- Conditions
- Iron Deficiency, Iron Deficiency Anemia, Cognition
- Trial name
- NCT00741143
- Testing
- Fortification of wheat flour with NaFeEdta
- Where
- India
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- St. John's Research Institute
Neonatal Hyperbilirubinemia
Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency
Neonatal Glucose-6-phosphate Dehydrogenase(G6PD) Deficiency is one of the significant reason for neonatal hyperbilirubinemia and even irreversible bilirubin encephalopathy.The neonates may be attacked due to acute infection…
- Trial name
- NCT02594904
- Testing
- Yinzhihuang Oral Liquid
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Southern Medical University, China
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Investigation of Clofarabine in Acute Leukemias
The goals and objectives of this project are to evaluate the antileukemic activity of the investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00098033
- Testing
- clofarabine
- Volunteers
- 64 people
- Sponsor
- University of Texas
Myeloid Leukemia
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML.
- Trial name
- NCT07604233
- Testing
- Fludarabine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Disease
Early Application of CPAP in Hematologic
The purpose of this study is to evaluate the use of CPAP in the prevention of acute respiratory failure in neutropenic ( or hematologic malignancy ) patients .CPAP applied preventively in hematological patients with high risk of…
- Trial name
- HEMOCPAP (NCT00507533)
- Testing
- Continuous positive airway pressure
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Turin, Italy
Lupus Erythematosus, Systemic, Purpura, Thrombocytopenic, Idiopathic
Optimization of Glucocorticoid Taper Strategies for SLE-ITP
SLE associated immune thrombocytopenia (SLE-ITP) is one of the main clinical manifestations of SLE. Approximately 70% of SLE patients follow a relapsing-remitting course. Similarly, SLE-ITP often relapses during GCs tapering.
- Conditions
- Lupus Erythematosus, Systemic, Purpura, Thrombocytopenic, Idiopathic, Glucocorticoids, Adverse Effect of Glucocorticoids
- Trial name
- NCT05506033
- Testing
- rapid GCs taper
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University Union Hospital
Multiple Myeloma and Malignant Lymphoma
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.
- Trial name
- NCT05007652
- Testing
- KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor)
- Where
- 21 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Leukemia, Myeloid, Acute
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.
- Trial name
- NCT01632852
- Testing
- CSL362
- Where
- 5 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- CSL Limited
Aplastic Anemia, Transfusion-dependent Anemia
Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
Investigating the efficacy and safety of rhTPO in combination with cyclosporine versus cyclosporine alone for the treatment of TD-NSAA
- Trial name
- NCT06525948
- Testing
- rhTPO, Cyclosporin A
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking Union Medical College Hospital
Sickle Cell Disease
MACS Study - Microparticles and Coagulation in Sickle Cell Disease
Sickle cell disease (SCD) is an inherited disorder of the red blood cell. It is now the commonest genetic disorder in the UK and of childhood stroke, with up to 40% of children having a stroke (clinical or picked up on a scan) by…
- Trial name
- MACS (NCT01242878)
- Where
- 3 sites in United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University College, London
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete…
- Conditions
- Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
- Trial name
- NCT01158885
- Testing
- Clofarabine, Cytarabine intravenous, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
Leukemia, Myeloid, Acute
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
This is an open-label, dose-escalating trial to evaluate the MTD and/or dose to be used for further development by evaluation of DLT in course 1 and the safety of volasertib when added to standard intensive salvage chemotherapy…
- Trial name
- NCT02722135
- Testing
- Volasertib
- Where
- Belgium
- Sponsor
- Boehringer Ingelheim
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.